Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B
Status:
Completed
Trial end date:
2015-11-06
Target enrollment:
Participant gender:
Summary
This is a multicenter, double blind, active-controlled, randomized, parallel group study to
demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for
patients with HBeAg Chronic Hepatitis B. The subject will receive two tablets daily for 48
days.
Phase:
Phase 4
Details
Lead Sponsor:
Dong-A Pharmaceutical Co., Ltd. Dong-A ST Co., Ltd.